Introduction

The financial landscape of the pharmaceutical industry is ever-changing, and Martin and Harris have been a significant player in this sector. The company has recently released its financial results for the fiscal year 2023, and there are some interesting takeaways. While the company has shown a decent growth in revenue, the Profit After Tax (PAT) and Earnings Per Share (EPS) have remained flat. In this article, we will delve deep into the financials of Martin and Harris, focusing on key metrics like revenue, PAT, and EPS. We will also discuss the impact of increased expenses on the company's bottom line.

Revenue Growth: A Positive Sign

On a standalone basis, Martin and Harris have reported a revenue of 207 Cr for FY23, which is a commendable 20% increase from the 172 Cr in FY22. This growth indicates a strong performance in the company's core pharma business and suggests that the company has been able to capitalize on market opportunities effectively.

Flat Profit: A Closer Look

Despite the impressive revenue growth, the company's PAT remained flat at 53 Cr. The reason behind this stagnation can be traced back to the Profit and Loss (P&L) statement. The employee benefit expenses have increased from 18 Cr in FY22 to 24 Cr in FY23. Additionally, other expenses have surged from 44 Cr to 60 Cr in the same period. This amounts to an overall increase in expenses by almost 22 Cr.

Breakdown of Expenses

A significant portion of the increased expenses comes from legal and professional fees, along with consultancy charges, which have seen a 7 Cr increase. These rising costs have offset the revenue growth, leading to a flat PAT and EPS.

Subsidiary Performance: Delite Infrastructure

Delite Infrastructure, a subsidiary of Martin and Harris, primarily earns its income from Rent and Interest. The income for FY23 remained around 21 Cr, similar to the 25 Cr in the previous year.

Consolidated Financials

On a consolidated level, the revenue for FY23 was 229 Cr compared to 212 Cr in FY22. The PAT was 68 Cr in FY23, slightly lower than the 70 Cr in FY22. The EPS for FY23 stood at approximately 170.

Conclusion: A Mixed Bag

To sum up, Martin and Harris have shown promising growth in their pharma business with a 20% increase in revenue. However, the increased expenses have negated the impact of this growth on the PAT. Investors looking at Martin and Harris Unlisted Share Price should consider these factors carefully. For those interested in investing in Martin and Harris Unlisted Share, it's crucial to weigh the growth prospects against the rising operational costs. While the top line shows promise, the bottom line needs careful evaluation